Introduction
============

In metastatic breast cancer (mBC), selection of the most appropriate endpoint for clinical trials is becoming increasingly important when evaluating new first-line therapies. In HER2-positive mBC, for which a number of targeted agents exist, several trials across treatment settings have demonstrated overall survival (OS) benefits from HER2-directed therapies.[@b1-cmar-10-5423] In HER2-negative mBC, however, where the target is less clear and patient selection is more challenging, progression-free survival (PFS) benefits have rarely translated into statistically significant OS benefits. To date, no Phase III trial evaluating antiangiogenic agents, cyclin-dependent kinase 4/6 inhibitors, mTOR inhibitors, or poly(adenosine diphosphate--ribose) polymerase inhibitors has shown a statistically significant OS improvement. OS is considered an unambiguous endpoint and is the global gold standard for demonstrating clinical benefit. However, extending life is not necessarily valuable if accompanied by significant quality of life (QoL) deterioration. Other disadvantages of OS as a primary endpoint are bias caused by treatment evolution during long studies, the diluting effect of crossover, numerous heterogeneous subsequent treatment lines, and the need for large patient numbers and/or long follow-up before obtaining results. This is particularly problematic in first-line trials, in which patients typically receive multiple treatment lines after progression.[@b2-cmar-10-5423],[@b3-cmar-10-5423] Consequently, authorities including the European Medicines Agency accept PFS as a relevant endpoint and approve drugs based on PFS benefit.

The correlation between PFS and OS appears to be less robust in settings with longer postprogression survival and/or effective subsequent therapies,[@b4-cmar-10-5423]--[@b6-cmar-10-5423] whereas in later treatment lines, the likelihood of showing an OS benefit increases.[@b7-cmar-10-5423],[@b8-cmar-10-5423] However, a recent analysis of 40 randomized controlled trials in HER2-negative hormone receptor-positive mBC indicated a significant association between PFS/time to progression (TTP) and OS, irrespective of treatment line.[@b9-cmar-10-5423] To explore this topic further, we used published data from contemporary HER2-negative mBC trials to calculate the sample sizes required to power for OS compared with sample sizes actually used. Based on our findings, we discuss the challenges of designing trials in HER2-negative mBC, where powering for OS is sometimes unrealistic, unfeasible, or unfundable, with the aim of improving future trial planning and design.

Design
======

Clinical trials were identified from a systematic search of MEDLINE (details in [Table S1](#SD1-cmar-10-5423){ref-type="supplementary-material"}) using the following criteria: randomized superiority trials; first-line chemotherapy or targeted therapy for HER2-negative mBC; \>150 patients; meeting the primary efficacy objective ("positive" trials); and published in English in a peer-reviewed journal between January 1, 2000 and February 15, 2018.

The sample sizes required to power for PFS/TTP and OS were calculated retrospectively for each trial using the observed median PFS/TTP and median OS in the treatment groups for treatment effect, the actual recruitment period, and the actual total study duration (α=0.05, two-sided log-rank test, 80% power). Dropout rates were not considered for sample size calculation. nQuery Advisor (version 7.0; Statistical Solutions Ltd, Cork, Ireland) was used for sample size calculations. If information on the total study duration was missing, we chose a simple pragmatic assumption that the study period was one-third longer than the recruitment duration.

The retrospectively calculated sample sizes were summarized as a factor (x) relative to the actual sample size. x \<1 would require x-fold fewer cases to show a significant benefit, whereas x \>1 required x-fold more cases.

Results
=======

Analysis data set
-----------------

Thirteen trials met the selection criteria ([Table 1](#t1-cmar-10-5423){ref-type="table"}). Of these, nine reported all information required for retrospective sample size calculation. In four reports (all published before 2006), insufficiently described study duration made it difficult or impossible to understand fully the statistical assumptions for sample size calculation. Only one trial had OS as the primary endpoint.

In most trials, the HRs showed a stronger treatment effect on PFS/TTP than OS ([Figure 1](#f1-cmar-10-5423){ref-type="fig"}). Four trials showed statistically significantly improved OS.[@b12-cmar-10-5423],[@b14-cmar-10-5423],[@b15-cmar-10-5423],[@b24-cmar-10-5423]

Retrospective sample size calculation
-------------------------------------

[Table 2](#t2-cmar-10-5423){ref-type="table"} shows the retrospectively calculated sample sizes required to show PFS/TTP and OS benefit with the observed data compared with the actual sample sizes. According to these calculations, six of 13 trials had sample sizes larger than required to demonstrate a significant PFS benefit. However, all would have required a larger sample size to demonstrate a significant OS benefit with the observed results. The increase in sample size ranged from 1.2-fold to 2,460-fold. In nine of the 12 trials with OS information, the calculated required sample size to demonstrate a significant OS benefit with the observed OS results was at least fivefold greater than the actual sample size. [Figure 2](#f2-cmar-10-5423){ref-type="fig"} summarizes the sample size increase required to show a significant OS benefit with the reported data.

In all but one trial, a larger sample size would be required to show OS than PFS benefit. In 10 of the 12 trials with available OS results, the sample size required to power for OS was at least fivefold larger than that needed to power for PFS.

Discussion
==========

Our analyses suggest that in the first-line HER2-negative mBC setting, it is a high hurdle to conduct a trial with adequate power to detect an OS improvement. Sample sizes to power for OS are usually extremely large and substantially larger than required to power for PFS.

The generally larger PFS than OS treatment effect in HER2-negative mBC is consistent with a recently reported study across various tumor types.[@b27-cmar-10-5423] Our findings are also consistent with reports in the literature suggesting that demonstrating an OS benefit is becoming increasingly unrealistic in contemporary clinical trials.[@b2-cmar-10-5423] A trial without crossover may answer the question of OS most cleanly. However, if the investigational agent has shown clear activity, the possibility of crossover has to be discussed. An Independent Data Monitoring Committee may feel obliged to stop a trial because of a clear signal, but it will then be impossible to conclude on the secondary endpoint of OS. Furthermore, a second trial of the same agent cannot be conducted after proven benefit because it is difficult to consent patients to be randomized between an experimental agent and a control arm known to be inferior. At times of rapid innovation, endpoints allowing prompt application of therapy optimization to standard clinical care are required. Therefore, it is important to determine whether progression-based endpoints are suitable for demonstrating utility. Available endpoints include PFS, TTP, and time to treatment failure. These allow earlier provision of study results and can be more sensitive indicators of treatment benefit because they are not affected by further treatment lines or crossover.[@b28-cmar-10-5423],[@b29-cmar-10-5423] Another benefit is comparability, as PFS is currently the most commonly used primary endpoint in Phase III trials. However, there is no clear evidence that PFS is a surrogate for OS.

In a recent analysis of PFS and OS in 58 randomized Phase II/III trials evaluating first-line systemic therapy for HER2-negative hormone receptor-positive mBC, several factors besides first-line therapy were reported to influence OS.[@b30-cmar-10-5423] These included prior endocrine therapy, prior (neo)adjuvant chemotherapy, types and lines of postprogression therapy, as well as disease characteristics associated with prognosis. Geographic region also influenced OS, presumably because of differences in healthcare patterns, management, and access in different countries.

In our analysis, the trial in which the actual sample size and the retrospectively calculated sample size for OS were most similar was IMELDA, a maintenance trial evaluating the addition of capecitabine to maintenance bevacizumab after bevacizumab/taxane induction therapy as a new treatment approach.[@b24-cmar-10-5423] In these patients already demonstrating chemosensitivity to induction therapy, switching to capecitabine before progression potentially anticipates development of resistance. In IMELDA, a significant OS benefit was demonstrated with a relatively small sample size but the retrospectively calculated sample size suggested that a larger sample size was needed. This is explained by differences in the methodology used for sample size calculation compared with the trial analysis method. Importantly, sample size calculation is only an estimation. Conversely, trial outcome is not proof and there is 5% error for demonstrating a significant benefit.

There appeared to be a gradual increase in median OS in the investigational arm over time ([Table 2](#t2-cmar-10-5423){ref-type="table"}). Such cross-trial comparisons have obvious limitations, particularly when including maintenance vs treatment strategies. Nevertheless, median OS with experimental therapy remained \<2 years in all trials evaluating chemotherapy alone, crossing the 2-year threshold only with the introduction of targeted therapy (bevacizumab). This presumably reflects not only treatment effect but also earlier diagnosis, better disease management, and an increase in the number of subsequent therapy options available. Indeed, similar increases in median OS can be seen in the control arm.

Given these challenges, how should we test effectiveness most appropriately in the first-line HER2-negative mBC setting? While Health Technology Assessment bodies worldwide accept PFS as a meaningful endpoint for clinical trials, progression-based outcomes are not recognized in Germany by the Institute for Quality and Efficiency in Health Services and the Joint Federal Committee (G-BA). These organizations focus on QoL, safety, OS, and morbidity, whereas PFS alone is not considered a meaningful endpoint, nor (in contrast with the clinical view) as an aspect of morbidity. The rationale for the G-BA's stance is that superior progression-based outcomes evaluated by imaging are not considered to represent relevant benefits for patients. Patient relevance is accepted only if progression is recorded, for example, through symptoms perceptible to the patient. However, guidelines recommend assessing tumor burden every 8 weeks to allow prompt detection of metastatic progression, discontinuation of ineffective treatment with associated side effects, and prevention of tumor-associated symptoms that could be avoided by a change of treatment or strategy.[@b31-cmar-10-5423]

Irrespective of surrogacy for OS, many believe that PFS is an important and relevant outcome for patients, associated with improved overall QoL, physical functioning, and emotional well-being.[@b32-cmar-10-5423] Extending PFS was ranked as more important than tumor shrinkage, limiting side effects, or treatment frequency in a questionnaire-based survey. Self-rated QoL was the highest after respondents had been told that their disease was responding to treatment. Therefore, progression-based parameters should generally be accepted as patient-relevant endpoints. Furthermore, changing therapy at progression affects patients' lives. A new therapy may be associated with new side effects and/or a new treatment schedule and mode of administration. The consequences of disease progression are depressive reactions, grief, and despair. The possibility of tumor control is the most important reason for patients agreeing to systemic therapy.[@b33-cmar-10-5423] Fear of disease progression is the most commonly reported psychological burden in patients.[@b34-cmar-10-5423]

We acknowledge that PFS is not a perfect endpoint, potentially being influenced by assessment intervals, choice of target lesions, and measurement technology. Some of these challenges are overcome by Independent Central Review, which is important for accepting PFS as an endpoint. Regarding the limitations of OS, several elegant biostatistical methods have been developed to account for crossover, such as inverse probability of censoring weighting (IPCW) and the rank-preserving structural failure time (RPSFT) model.[@b35-cmar-10-5423],[@b36-cmar-10-5423] However, these approaches are not flawless: IPCW assumes that there are no unknown or unmeasured confounding factors that could influence crossover and OS, whereas RPSFT assumes that the effect of treatment is constant across time and/or treatment lines. No single validated standard for statistical correction of crossover has been established in settings with long postprogression survival.

With the increasing use of maintenance therapies, eg, in ovarian cancer, alternatives to PFS and OS have emerged, including intermediate endpoints such as time to second progression or time to first or second subsequent therapy.[@b37-cmar-10-5423] These endpoints merit consideration in future trial designs in HER2-negative mBC. For trials evaluating endocrine therapies, time to first chemotherapy can also be a valuable endpoint, with clear patient relevance. Alternative endpoints used in other tumor types include quality-adjusted time without symptoms or toxicity and quality-adjusted PFS. However, it is essential that any endpoint is clearly defined and that the precise definition is used consistently across trials measuring the effect of treatment.[@b38-cmar-10-5423] Changes in molecular markers may also be of interest as surrogate endpoints.

In an attempt to quantify the medical benefits of new drugs, composite scales including pharmacoeconomic parameters have been introduced, such as the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)[@b39-cmar-10-5423] and the American Society of Clinical Oncology Value Framework.[@b40-cmar-10-5423] A recent survey indicated that many trials demonstrating statistically significant improvements in efficacy did not meet the ESMO-MCBS clinical benefit threshold,[@b41-cmar-10-5423] particularly trials in the palliative setting.

The challenge of large sample sizes required to show OS improvement in clinical trials has been accompanied by increased interest in real-world data (RWD). In some cases, RWD evaluation has suggested improved OS from a treatment despite the lack of OS benefit in prospective randomized clinical trials.[@b42-cmar-10-5423] The main advantages of RWD are the very large sample sizes available for analysis and inclusion of broader, more heterogeneous patient populations with common comorbidities than is possible in a clinical trial, reflecting populations presenting in routine oncology practice. However, there are many limitations and even with sophisticated statistical methodology, RWD are exposed to important potential biases.[@b43-cmar-10-5423] Therefore, RWD can be viewed only as complementary to randomized clinical trials, not as an alternative.

A limitation of our analysis is the focus on chemotherapy and antiangiogenic agents. Numerous ongoing trials in the first-line HER2-negative mBC setting are evaluating cancer immunotherapy agents, which have a different mode of action and thus may exhibit different effects on PFS and OS. Furthermore, many of these trials focus on triple-negative mBC, a slightly more homogeneous population with shorter OS expectancy, shorter postprogression survival, and fewer treatment options after progression. All of these factors may affect the ability to demonstrate a significant OS effect, and, therefore, the patterns observed in our analysis may not predict future trials of cancer immunotherapy. Interestingly, several ongoing Phase III trials of immunotherapy in triple-negative mBC evaluate OS as the (co)primary endpoint. Another potential criticism is that the proportion of patients completing treatment is not taken into account. This information is missing in some of the publications, particularly in the older trials, but may have an impact on outcomes.

Conclusion
==========

Although there are many reasons why OS is an attractive endpoint in trials of first-line therapy for HER2-negative mBC, it has limitations. Designing trials to test potential new treatments for HER2-negative mBC is challenging and requires a balance of regulatory acceptability, feasibility, and realistic medical assumptions to calculate sample sizes, which can be particularly difficult in heterogeneous study populations with long postprogression survival and heterogeneous subsequent therapies. The magnitude of OS benefit likely to be considered as clinically (as well as statistically) significant depends on disease biology and risk. For example, in patients with triple-negative mBC, a 3-month improvement in median OS is undoubtedly meaningful, whereas in hormone receptor-positive mBC, a larger (6-month) improvement may be required to provide convincing meaningful benefit. In the current environment amid soaring costs and fierce competition,[@b44-cmar-10-5423] it is probably unrealistic to aim for trials demonstrating statistically significant OS improvement in this setting, except for trials in very specific poor prognosis populations. Ultimately, identification of robust alternative endpoints reflecting relevant patient benefits remains critical.

Data availability
=================

All data used for the analyses reported in this paper are taken from the cited publications.

Supplementary material
======================

###### 

Search strategy for identification of eligible trials

  Set\#   Searched for                                                                                                                                                                                                Results
  ------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------
  S1      MESH.EXACT.EXPLODE("Breast Neoplasms")                                                                                                                                                                      260,430
  S2      ti,ab((breast OR mamma\*) NEAR/2 (cancer\* OR carcinoma\* OR tumo\* OR neoplasm\* or neoplasm\* or malignanc\*)) AND dstat.exact("Publisher" OR "In Process" OR "PubMed not MEDLINE" OR "In Data Review")   32,411
  S3      s1 or s2                                                                                                                                                                                                    292,808
  S4      ti,ab(metasta\* or mBC or dissemin\* or spread or advanced) AND s3                                                                                                                                          66,764
  S5      MESH.EXACT.EXPLODE("Neoplasm Metastasis") AND s3                                                                                                                                                            31,899
  S6      s4 or s5                                                                                                                                                                                                    78,519
  S7      s6 AND rtype.exact("Randomized Controlled Trial")                                                                                                                                                           2,832
  S8      all(randomized) AND s6                                                                                                                                                                                      5,803
  S9      all(placebo) AND s6                                                                                                                                                                                         475
  S10     s7 or s8 or s9                                                                                                                                                                                              5,920
  S11     (s7 or s8 or s9) AND rtype.exact("Clinical Trial, Phase III" OR "Clinical Trial, Phase II")                                                                                                                 969
  S12     (ti,ab(phase p/2 III\[\*1\] or phase p/2 3\[\*1\] or phase p/2 II\[\*4\] or phase p/2 2\[\*4\]) AND s10)                                                                                                    1,468
  S13     (s12) and (dstat.exact("Publisher" OR "In Process" OR "PubMed not MEDLINE" OR "In Data Review"))                                                                                                            126
  S14     (s11 or s13)                                                                                                                                                                                                1,095
  S15     ((s11 or s13)) and (pd(2014-2018))                                                                                                                                                                          348

Medical writing support was provided by Jennifer Kelly, MA (Medi-Kelsey Ltd, Ashbourne, UK) and funded by Roche Pharma AG. This work was funded by Roche Pharma AG, Grenzach-Wyhlen, Germany. A poster reporting a preliminary analysis of this topic was presented at the European Society for Medical Oncology (ESMO) congress in Madrid, Spain; 8--12 September, 2017. The abstract from the poster was published in the congress proceedings.[@b45-cmar-10-5423]
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![Summary of PFS/TTP and OS HRs across trials. Vertical bars represent 95% CIs, except for MERiDiAN, which shows the 99% CI reported for this coprimary endpoint.\
**Abbreviations:** OS, overall survival; PFS, progression-free survival; TTP, time to progression.](cmar-10-5423Fig1){#f1-cmar-10-5423}

![Additional patients required to show an OS benefit^a^.\
**Note:** ^a^One study[@b19-cmar-10-5423] is not shown on the figure as the numbers are so large (x=2,460.2, retrospectively calculated increase in sample size =1,846,875).\
**Abbreviation:** OS, overall survival.](cmar-10-5423Fig2){#f2-cmar-10-5423}

###### 

Overview of trials included in the analysis. Trials are ordered according to date enrollment began (earliest first)

  Trial                                                                                          Recruitment period   Control arm (A)                                                    Experimental arm (B)                                                                               Missing information for retrospective sample size calculation   Reported sample size calculation   Primary endpoint   Data cutoff for primary analysis   HR for PFS/TTP (95% CI)   HR for OS (95% CI)                     Median duration of follow-up, months                       
  ---------------------------------------------------------------------------------------------- -------------------- ------------------------------------------------------------------ -------------------------------------------------------------------------------------------------- --------------------------------------------------------------- ---------------------------------- ------------------ ---------------------------------- ------------------------- -------------------------------------- -------------------------------------- ------------------- ---------------------------------
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  HEPI 013[@b10-cmar-10-5423]                                                                    Sep 1990--Nov 1992   Cyclophosphamide, methotrexate, fluorouracil                       Cyclophosphamide, epirubicin, fluorouracil                                                         Yes[a](#tfn1-cmar-10-5423){ref-type="table-fn"}                 0.73                               80                 155/420                            TTP                       NR                                     0.73 (0.59--0.92)                      0.87 (0.70--1.10)   \>20
  SBG 9403[@b11-cmar-10-5423]                                                                    Feb 1995--Jan 1999   Epirubicin                                                         Vinorelbine + epirubicin                                                                           Yes                                                             NR                                 NR                 NR                                 PFS                       NR                                     0.75 (0.61--0.92)                      NR                  42 (A)/43 (B)
  Jassem et al 2001[@b12-cmar-10-5423]                                                           Nov 1996--Apr 1998   Fluorouracil, doxorubicin, cyclophosphamide                        Doxorubicin + paclitaxel                                                                           Yes[a](#tfn1-cmar-10-5423){ref-type="table-fn"}                 0.67                               80                 192/260                            TTP                       NR                                     0.74 (0.56--0.98)                      0.68 (0.51--0.93)   29
  von Minckwitz et al 2005[@b13-cmar-10-5423]                                                    Nov 1996--Sep 2001   Cyclophosphamide, methotrexate, fluorouracil                       Bendamustine, methotrexate, fluorouracil                                                           Yes                                                             NR                                 NR                 NR/296                             TTP                       NR                                     NR                                     NR                  NR
  Bontenbal et al 2005[@b14-cmar-10-5423]                                                        Mar 1997--Apr 2002   Fluorouracil, doxorubicin, cyclophosphamide                        Doxorubicin + docetaxel                                                                            No                                                              0.67                               80                 201/260                            TTP                       NR                                     0.67 (0.51--0.88)                      0.70 (0.52--0.94)   27 (OS)/14 (TTP)
  Albain et al 2008[@b15-cmar-10-5423]                                                           Aug 1999--Apr 2002   Paclitaxel                                                         Gemcitabine + paclitaxel                                                                           No                                                              0.75                               80                 377/526                            OS                        NR                                     0.70 (0.59--0.85)                      0.82 (0.67--1.00)   NR
  E2100[@b16-cmar-10-5423]--[@b18-cmar-10-5423]                                                  Dec 2001--May 2004   Paclitaxel                                                         Bevacizumab + paclitaxel                                                                           No                                                              0.75                               85                 546/685                            PFS                       Feb 9, 2005 (PFS)/Oct 21, 2006 (OS)    0.48 (0.40--0.61)                      0.87 (NR)           NR
  Sparano et al 2009[@b19-cmar-10-5423]                                                          Sep 2004--Nov 2006   Docetaxel                                                          Pegylated liposomal doxorubicin + docetaxel                                                        No                                                              0.77                               \>80               485/720                            TTP                       NR                                     0.65 (0.55--0.77)                      1.02 (0.86--1.22)   NR
  RIBBON-1[b](#tfn1-cmar-10-5423){ref-type="table-fn"},[@b20-cmar-10-5423],[@b21-cmar-10-5423]   Dec 2005--Aug 2007   Capecitabine                                                       Bevacizumab + capecitabine                                                                         No                                                              0.75                               80                 405/600                            PFS                       Jul 31, 2008                           0.69 (0.56--0.84)                      0.88 (0.69--1.13)   16 (PFS)/23 (OS)
  AVADO[c](#tfn3-cmar-10-5423){ref-type="table-fn"},[@b22-cmar-10-5423]                          Mar 2006--Apr 2007   Docetaxel                                                          Bevacizumab + docetaxel                                                                            No                                                              0.70                               80                 430/669                            PFS                       NR                                     0.77 (0.64--0.93)                      1.03 (0.70--1.33)   25
  ATX (BOOG 2006-06)[@b23-cmar-10-5423]                                                          Jun 2007--Dec 2010   Paclitaxel + bevacizumab induction, then bevacizumab maintenance   Paclitaxel + bevacizumab + capecitabine induction, then bevacizumab and capecitabine maintenance   No                                                              0.81                               80                 NR/303                             PFS                       Apr 26, 2013                           0.52 (0.41--0.67)                      0.92 (0.72--1.19)   41
  IMELDA[@b24-cmar-10-5423]                                                                      Jul 2009--Mar 2011   Docetaxel + bevacizumab induction, then bevacizumab maintenance    Docetaxel + bevacizumab induction, then capecitabine + bevacizumab maintenance                     No                                                              0.70                               80                 244/290                            PFS                       Oct 4, 2013                            0.38 (0.27--0.55)                      0.43 (0.26--0.69)   30 (A)/32 (B)
  MERiDiAN[@b25-cmar-10-5423],[@b26-cmar-10-5423]                                                Aug 2012--Dec 2013   Paclitaxel                                                         Paclitaxel + bevacizumab                                                                           No                                                              0.67                               85                 326/480                            PFS                       Nov 30, 2014 (PFS)/Apr 28, 2017 (OS)   0.68 (99% CI 0.51--0.91)               0.94 (0.75--1.18)   15 (PFS)/24 (A) and 23 (B) (OS)

**Notes:**

Total study duration missing.

Data reported for capecitabine cohort (anthracycline/taxane cohort not included because of heterogeneity of chemotherapy backbone).

Data reported for comparison of bevacizumab 15 mg/kg vs placebo (bevacizumab 7.5 mg/kg not included in this analysis as there was no significant improvement in the primary endpoint) but events/patients for reported sample size calculations include all three treatment arms as reported in the statistical design section of the publication.

**Abbreviations:** NR, not reported; OS, overall survival; PFS, progression-free survival; TTP, time to disease progression.

###### 

Summary of trial outcomes

  Trial                                                                   Total no of patients in trial   Observed median, months (arm A vs arm B)                                                              Retrospectively calculated sample size   Factor (x)                                                                                                                          
  ----------------------------------------------------------------------- ------------------------------- ----------------------------------------------------------------------------------------------------- ---------------------------------------- ------------------------------------------------------------------------------------------------------ ------- ----------- -------- --------
                                                                                                                                                                                                                                                                                                                                                                                             
  HEPI 013[@b10-cmar-10-5423]                                             460                             --                                                                                                    6.3 vs 8.7                               18.2 vs 20.1                                                                                           360     5,906       12.8     16.4
  SBG 9403[@b11-cmar-10-5423]                                             387                             8.2 vs 10.1                                                                                           --                                       18.0 vs 19.1                                                                                           788     11,988      31.0     15.2
  Jassem et al 2001[@b12-cmar-10-5423]                                    267                             --                                                                                                    6.2 vs 8.3                               18.3 vs 23.3                                                                                           506     1,402       5.3      2.8
  von Minckwitz et al 2005[@b13-cmar-10-5423]                             345                             --                                                                                                    6.7 vs 8.2                               --                                                                                                     792     --          --       --
  Bontenbal et al 2005[@b14-cmar-10-5423]                                 216                             --                                                                                                    6.6 vs 8.0                               16.2 vs 22.6                                                                                           1,022   476         2.2      0.5
  Albain et al 2008[@b15-cmar-10-5423]                                    529                             --                                                                                                    4.0 vs 6.1                               15.8 vs 18.6                                                                                           168     1,404       2.7      8.4
  E2100[@b16-cmar-10-5423],[@b17-cmar-10-5423]                            722                             5.8 vs 11.3                                                                                           --                                       24.8 vs 26.5                                                                                           74      10,396      14.4     140.5
  Sparano et al 2009[@b19-cmar-10-5423]                                   751                             --                                                                                                    7.0 vs 9.8                               20.6 vs 20.5                                                                                           294     1,847,626   2460.2   6284.4
  RIBBON-1[@b20-cmar-10-5423],[@b21-cmar-10-5423]                         615                             5.7 vs 8.6                                                                                            --                                       22.8 vs 25.7                                                                                           264     6,000       9.8      22.7
  AVADO[a](#tfn5-cmar-10-5423){ref-type="table-fn"},[@b22-cmar-10-5423]   488                             8.2 vs 10.1                                                                                           --                                       31.9 vs 30.2                                                                                           806     21,136      43.3     26.2
  ATX (BOOG 2006-06)[@b23-cmar-10-5423]                                   312                             8.4 vs 11.2                                                                                           --                                       23.1 vs 24.2                                                                                           440     24,178      77.5     55.0
  IMELDA[@b24-cmar-10-5423]                                               185                             4.3[a](#tfn5-cmar-10-5423){ref-type="table-fn"} vs 11.9[a](#tfn5-cmar-10-5423){ref-type="table-fn"}   --                                       23.7[a](#tfn5-cmar-10-5423){ref-type="table-fn"} vs 39.0[a](#tfn5-cmar-10-5423){ref-type="table-fn"}   32      214         1.2      6.7
  MERiDiAN[@b25-cmar-10-5423],[@b26-cmar-10-5423]                         481                             8.8 vs 11.0                                                                                           --                                       25.8 vs 28.8                                                                                           866     6,728       14.0     7.8

**Notes:**

Median values are not comparable with the other trials, first because PFS and OS were calculated from the time of randomization to maintenance therapy rather than the start of first-line therapy, and second because only patients with response or stable disease after induction therapy were included in the randomized population.

**Abbreviations:** OS, overall survival; PFS, progression-free survival; TTP, time to disease progression.
